Hoth Therapeutics (NASDAQ: HOTH) has filed two U.S. provisional patent applications to expand its intellectual property in treating skin toxicities from modern cancer therapies. These filings leverage lead candidate HT-001 to address radiation dermatitis and side effects from targeted treatments like menin inhibitors, establishing a novel oncology-adjacent dermatology platform.
Glimpse:
Announced January 2, 2026, the patents protect topical applications of HT-001 a receptor antagonist targeting neurogenic inflammation for radiation-induced skin damage and toxicities from emerging oncology drugs. This strategic move positions Hoth to capture growing demand in supportive oncodermatology, where current options are limited, while enabling broader applications in inflammatory skin disorders.
Hoth Therapeutics, a clinical-stage biopharmaceutical company focused on underserved therapeutic areas, has strengthened its pipeline by filing two U.S. provisional patent applications that significantly broaden its intellectual property footprint. The filings, disclosed on January 2, 2026, center on repurposing HT-001 a well-characterized compound for managing severe dermatologic side effects commonly associated with advanced cancer treatments.
The first patent covers topical treatment of radiation-induced skin toxicity, a frequent complication in radiotherapy patients causing painful dermatitis, inflammation, and infection risk often leading to dose reductions or interruptions.
The second targets dermatologic toxicities from targeted therapies, including second- and third-generation menin inhibitors (emerging in leukemia and solid tumors) and other agents that trigger rashes, pruritus, and impaired quality of life.
These conditions affect a substantial portion of oncology patients, yet lack mechanism-specific therapies beyond symptomatic relief. HT-001’s profile as a receptor antagonist positions it to interrupt underlying neurogenic and inflammatory pathways, potentially improving adherence to life-saving cancer regimens.
Hoth views the patents as foundational for a scalable oncology-dermatology platform with applications in radiation oncology, targeted therapies, general dermatology, and inflammatory conditions. The filings allow flexibility for formulation refinements, preclinical optimization, and future full U.S./international protection.
CEO Robb Knie commented: “These filings represent a meaningful expansion of our intellectual property estate into an increasingly important area of oncology care. As cancer therapies advance, the ability to manage treatment-related toxicities is becoming essential.”
This development builds on HT-001’s ongoing Phase II trial for EGFR-inhibitor rashes (showing favorable safety/efficacy) and aligns with Hoth’s strategy of IP-driven value creation in high-unmet-need markets.
Here are visuals representing oncology supportive care, dermatologic toxicities, and innovative topical therapies:
“These filings represent a meaningful expansion of our intellectual property estate into an increasingly important area of oncology care.”
By
HB Team
Related News
